Thermo Fisher Scientific agrees manufacturing deal with Juno Therapeutics

Thermo Fisher Scientific has formed a new seven-year non-exclusive licensing and supply agreement with Juno Therapeutics to aid the production of chimeric antigen receptor T cell (CAR T) therapies.

Under the terms of the deal, Juno will be able to use Thermo Fisher Scientific's Cell Therapy Systems activation reagents in the production of CAR T therapies, helping the company to deliver high-quality therapeutic options to patients as quickly as possible.

Juno will use CTS Dynabeads CD3/CD28 magnetic beads to activate and expand T cells that have been genetically engineered to recognise and fight cancer cells in each individual patient.

This platform facilitates the research, development and commercialisation of CAR T cell therapies by providing a scalable system for streamlining production, while ensuring high reproducibility.

Mark Stevenson, chief operating officer at Thermo Fisher Scientific, said: "Cell Therapy Systems' products help minimise the risk of contamination and variability in clinical research and drug commercialisation. These products are supported by rigorous regulatory review, making them a proven choice as more companies invest in moving from bench to bedside."

With over 20 years of experience within the science market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.